Volume 97, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

There is no abstract available for this article.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Eick-Cost AA, Hu Z, Rohrbeck P, Clark LL, 2017. Neuropsychiatric outcomes after mefloquine exposure among U.S. military service members. Am J Trop Med Hyg 96: 159166.[Crossref]
    [Google Scholar]
  2. Nevin RL, 2015. Mefloquine and posttraumatic stress disorder. Ritchie EC, ed. Textbook of Military Medicine. Forensic and Ethical Issues in Military Behavioral Health. Washington, DC: Borden Institute, 277–296. Available at: http://www.cs.amedd.army.mil/FileDownloadpublic.aspx?docid=59eea54e-292d-4a35-9117-d9be6c40dac3.
  3. Livezey J, Oliver T, Cantilena L, 2016. Prolonged neuropsychiatric symptoms in a military service member exposed to mefloquine. Drug Saf Case Rep 3: 7.
  4. Nevin RL, 2012. Falling rates of malaria among U.S. military service members in Afghanistan substantiate findings of high compliance with daily chemoprophylaxis. Am J Trop Med Hyg 87: 957958.[Crossref]
    [Google Scholar]
  5. Nevin RL, Ritchie EC, 2016. FDA Black Box, VA Red Ink? A successful service-connected disability claim for chronic neuropsychiatric adverse effects from mefloquine. Fed Pract 33: 2024. Available at: http://www.mdedge.com/fedprac/article/114732/mental-health/fda-black-box-va-red-ink-successful-service-connected.
    [Google Scholar]
  6. Nevin RL, 2010. Mefloquine prescriptions in the presence of contraindications: prevalence among US military personnel deployed to Afghanistan, 2007. Pharmacoepidemiol Drug Saf 19: 206210.[Crossref]
    [Google Scholar]
  7. Nevin RL, Pietrusiak PP, Caci JB, 2008. Prevalence of contraindications to mefloquine use among USA military personnel deployed to Afghanistan. Malar J 7: 30.[Crossref]
    [Google Scholar]
  8. Wells TS, Smith TC, Smith B, Wang LZ, Hansen CJ, Reed RJ, Goldfinger WE, Corbeil TE, Spooner CN, Ryan MA, 2006. Mefloquine use and hospitalizations among US service members, 2002–2004. Am J Trop Med Hyg 74: 744749.
    [Google Scholar]
  9. Nevin RL, Leoutsakos JM, 2017. Identification of a syndrome class of neuropsychiatric adverse reactions to mefloquine from latent class modeling of FDA adverse event reporting system data. Drugs R D 17: 199210.[Crossref]
    [Google Scholar]
  • Published online : 12 Jul 2017
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error